Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: March 22, 2022
Accepted: July 21, 2022
Published online: November 02, 2022

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 3

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Abstract

Introduction: High-flux hemodialysis membranes may modulate the cytokine storm of SARS-CoV-2, but their impact on chronic hemodialysis (CHD) patients is unknown. The aim of the study was the evaluation of asymmetric cellulose triacetate (ATA) and polymethylmethacrylate (PMMA) dialyzers on inflammatory markers and clinical outcomes in CHD patients with SARS-CoV-2. Methods: A prospective, observational study on CHD patients with SARS-CoV-2 was carried out. Patients were enrolled from March 2020 to May 2021. Pre- and postdialysis C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6) were determined at each session. Patients who underwent on-line hemodiafiltration (OLHDF) with a PMMA dialyzer were compared with those treated with OLHDF with a ATA dialyzer. The primary endpoint was the differences in the reduction ratio per session (RR) of CRP, PCT, IL-6, and IL-6 RR >25%. Results: We consecutively enrolled 74 CHD patients with COVID-19, 48 were treated with ATA membrane, and 26 with PMMA. Median IL-6 RR was higher in the ATA group compared to PMMA (17.08%, IQR −9.0 to 40.0 vs. 2.95%, IQR −34.63 to 27.32). Median CRP RR was 7.77% (IQR 2.47–13.77) in the ATA group versus 4.8% (IQR −2.65 to 11.38) in the PMMA group (p = 0.0017). Median PCT-RR% was 77.38% (IQR 70.92–82.97) in ATA group versus 54.59% (IQR 42.62–63.16) in the PMMA group (p < 0.0001). A multiple logistic regression analysis with IL-6 RR >25% as the outcome including the membrane employed, pre-dialysis IL-6, CRP, PCT, and ferritin showed that ATA led to a higher probability to reach the outcome (OR 1.891, 95% CI 1.273–2.840, p = 0.0018) while higher CRP favors the risk of lower IL-6 RR values (OR 0.910, 95% CI 0.868–0.949, p ≤ 0.0001). Conclusions: In SARS-CoV-2 CHD patients treated with OLHDF, ATA showed a better anti-inflammatory profile, regarding IL-6 RR, compared to PMMA.

© 2022 S. Karger AG, Basel

References Goffin E, Candellier A, Vart P, Noordzij M, Arnol M, Covic A, et al. COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. Nephrol Dial Transplant. 2021 Nov;36(11):2094–105. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug;584(7821):430–6. Nordio M, Reboldi G, Di Napoli A, Quintaliani G, Alberici F, Postorino M, et al. Risk factors and action thresholds for the novel coronavirus pandemic. Insights from the Italian Society of Nephrology COVID-19 Survey. J Nephrol. 2021 Apr;34(2):325–35. Bertrand D, Hamzaoui M, Lemée V, Lamulle J, Hanoy M, Laurent C, et al. Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients. J Am Soc Nephrol. 2021 Sep;32(9):2147–52. Attias P, Sakhi H, Rieu P, Soorkia A, Assayag D, Bouhroum S, et al. Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients. Kidney Int. 2021 Jun;99(6):1490–2. Santoro A, Guadagni G. Dialysis membrane: from convection to adsorption. Clin Kidney J. 2010 May;3(Suppl 1):i36–9. Aoike I. Clinical significance of protein adsorbable membranes: long-term clinical effects and analysis using a proteomic technique. Nephrol Dial Transplant. 2007 Jul;22(Suppl 5):v13–9. Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020 Oct;26(10):1636–43. Rampino T, Gregorini M, Perotti L, Ferrari F, Pattonieri EF, Grignano MA, et al. Hemoperfusion with CytoSorb as adjuvant therapy in critically ill patients with SARS-CoV2 pneumonia. Blood Purif. 2021;50(4–5):566–71. Maduell F, Navarro V, Cruz MC, Torregrosa E, Garcia D, Simon V, et al. Osteocalcin and myoglobin removal in on-line hemodiafiltration versus low- and high-flux hemodialysis. Am J Kidney Dis. 2002 Sep;40(3):582–9. National Kidney Foundation. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis. 2015;66(5):884–930. Grooteman MPC, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AHA, et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol. 2012 Jun;23(6):1087–96. Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant. 2013 Jan;28(1):192–202. Morena M, Jaussent A, Chalabi L, Leray-Moragues H, Chenine L, Debure A, et al. Treatment tolerance and patient-reported outcomes favor online hemodiafiltration compared to high-flux hemodialysis in the elderly. Kidney Int. 2017 Jun;91(6):1495–509. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras J, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013 Mar;24(3):487–97. Ronco C, Reis T, Cozzolino M. Rationale for medium cutoff membranes in COVID-19 patients requiring renal replacement therapy. Nephron. 2020;144(11):550–4. Esposito P, Cipriani L, Verzola D, Grignano MA, De Amici M, Testa G, et al. Effects of different dialysis strategies on inflammatory cytokine profile in maintenance hemodialysis patients with COVID-19: a randomized trial. J Clin Med. 2021 Mar;10(7):1383. Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007 Mar;18(3):886–95. Sunohara T, Masuda T. Fundamental characteristics of the newly developed ATATM membrane dialyzer. In: Kawanishi H, Takemoto Y, editors. Contributions to nephrology. S. Karger AG; 2017. p. 215–21. Singh A, Sonpar A. In adults exposed to COVID-19, hydroxychloroquine did not reduce confirmed or probable COVID-19: trial stopped for futility. Ann Intern Med. 2020 Oct;173(8):JC41. Bergström J, Wehle B. No change in corrected Β2-microglobulin concentration after cuprophane haemodialysis. Lancet. 1987 Mar;1(8533):628–9. National Kidney Foundation. KDOQI clinical practice guidelines for hemodialysisadequacy, update 2006. Am J Kidney Dis. 2006 Jul;48:S2–90. Quiroga B, Muñoz Ramos P, Giorgi M, Santos A, Núñez A, Ortiz A, et al. Dynamic assessment of interleukin-6 during hemodialysis and mortality in coronavirus disease-19. Ther Apher Dial. 2021 Dec;25(6):908–16. Zeng Z, Yu H, Chen H, Qi W, Chen L, Chen G, et al. Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. Crit Care. 2020 Dec;24(1):525. Naka T, Haase M, Bellomo R. “Super high-flux” or “high cut-off” hemofiltration and hemodialysis. Contrib Nephrol. 2010;166:181–9. Maduell F. Is there an “optimal dose” of hemodiafiltration? Blood Purif. 2015;40(Suppl 1):17–23. Cozzolino M, Magagnoli L, Ciceri P, Conte F, Galassi A. Effects of a medium cut-off (Theranova®) dialyser on haemodialysis patients: a prospective, cross-over study. Clin Kidney J. 2021;14(1):382–9. Weiner DE, Falzon L, Skoufos L, Bernardo A, Beck W, Xiao M, et al. Efficacy and safety of expanded hemodialysis with the Theranova 400 dialyzer: a randomized controlled trial. Clin J Am Soc Nephrol. 2020 Sep 7;15(9):1310–9. Atan R, Crosbie D, Bellomo R. Techniques of extracorporeal cytokine removal: a systematic review of the literature. Blood Purif. 2012;33(1–3):88–100. Girndt M, Heisel O, Kohler H. Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4-month long-term study. Nephrol Dial Transplant. 1999 Mar;14(3):676–82. Gu Y, Ding F, Qin H, Zhao H, Lin S. Synergetic effect of dialyzer membrane and lipopolysaccharide on peripheral blood mononuclear cell cytokine production in uremic patients. Chin Med J. 2000 Apr;113(4):315–9. Poppelaars F, Faria B, Gaya da Costa M, Franssen CFM, van Son WJ, Berger SP, et al. The complement system in dialysis: a forgotten story? Front Immunol. 2018 Jan;9:71. Angeletti A, Zappulo F, Donadei C, Cappuccilli M, Di Certo G, Conte D, et al. Immunological effects of a single hemodialysis treatment. Medicina. 2020 Feb;56(2):71. Sander A, Armbruster W, Sander B, Daul AE, Lange R, Peters J. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNFα plasma concentrations. Intensive Care Med. 1997 Aug;23(8):878–84. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020 Aug;81(2):e16–25. Houghton R, Moore N, Williams R, El-Bakri F, Peters J, Mori M, et al. C-reactive protein-guided use of procalcitonin in COVID-19. JAC Antimicrob Resist. 2021 Sep;3(4):dlab180. Alves-Filho JC, de Freitas A, Spiller F, Souto FO, Cunha FQ. The role of neutrophils in severe sepsis. Shock. 2008 Oct;30(7):3–9. Wei JX, Verity A, Garle M, Mahajan R, Wilson V. Examination of the effect of procalcitonin on human leucocytes and the porcine isolated coronary artery. Br J Anaesth. 2008 May;100(5):612–21. Yalın SF, Altıparmak MR, Dincer MT, Yadigar S, Murt A, Parmaksiz E, et al. Medium cut-off dialysis membranes: can they have impact on outcome of COVID-19 hemodialysis patients? Blood Purif. 2021;50(6):921–4. Tarakçıoğlu M, Erbağci AB, Usalan C, Deveci R, Kocabaş R. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines. Mediators Inflamm. 2003;12(1):15–9. De La Flor JC, Valga F, Marschall A, Monzon T, Albarracín C, Ruiz E, et al. Targeting cytokine storm in COVID-19: a role of online hemodiafiltration with asymmetric cellulose triacetate in maintenance hemodialysis patients – a report of 10 cases. Case Rep Nephrol. 2021 Mar;2021:1–7. Article / Publication Details

First-Page Preview

Received: March 22, 2022
Accepted: July 21, 2022
Published online: November 02, 2022

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 3

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU